AbbVie Research and Development Expenses 2010-2024 | ABBV

AbbVie research and development expenses for the twelve months ending June 30, 2024 were $7.537B, a 1.45% increase year-over-year.

  • AbbVie annual research and development expenses for 2023 were $7.675B, a 17.9% increase from 2022.
  • AbbVie annual research and development expenses for 2022 were $6.51B, a 5.95% decline from 2021.
  • AbbVie annual research and development expenses for 2021 were $6.922B, a 8.51% increase from 2020.

AbbVie Research and Development Expenses 2010-2024 | ABBV

  • AbbVie annual research and development expenses for 2023 were $7.675B, a 17.9% increase from 2022.
  • AbbVie annual research and development expenses for 2022 were $6.51B, a 5.95% decline from 2021.
  • AbbVie annual research and development expenses for 2021 were $6.922B, a 8.51% increase from 2020.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$861.3B
Novo Nordisk (NVO)$592.4B
Johnson & Johnson (JNJ)$402.2B
Merck (MRK)$299.6B
AstraZeneca (AZN)$243.5B
Novartis AG (NVS)$236.5B
Pfizer (PFE)$169B
Sanofi (SNY)$144.1B
Innoviva (INVA)$1.2B